All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RBM-007
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: AJU Pharma
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 17, 2020
Details:
Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the Territory.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Carotuximab
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2020
Details:
The companies said DE-122, when combined with Lucentis, did not meet the trial's main goal of improving visual acuity in patients with wet AMD compared to those taking Lucentis alone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RBM-007,Aflibercept
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2020
Details:
First patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
